ACCORDING TO THE FDA, THEY WILL
MAKE THE TEST AVAILABLE IN MOST
STATES IN THE COMING WEEKS.
PEOPLE WILL NEED TO HAVE A
DOCTOR'S ORDER TO BE ABLE TO
GET ONE OF THE AT-HOME TEST
KITS.
RIGHT NOW, A TEAM OF
DOCTORS AT THE UNIVERSITY OF
MIAMI IS WORKING ON WHAT COULD
BE GROUNDBREAKING THERAPY FOR
TREATING SOME COVID-19 PATIENTS.
WITH A FOCUS ON THOSE
SUFFERING WITH SEVERE LUNG
INFLAMMATION, THEY ARE USING
UMBILICAL CELLS TO TREAT
PATIENTS.
WE FIRST REPORTED ON THIS LAST
WEEKEND AND WE HAVE A CHANCE TO
GET AN UPDATE ON HOW IT IS
PROGRESSING.
THEY LEAD A TEAM OF
INTERNATIONAL SCIENTISTS AND HE
IS THE UNIVERSITY OF MIAMI
PROFESSOR AND SOME CELL THERAPY
RESEARCHER.
WE ARE SO GLAD TO HAVE YOU ON
TONIGHT.
THANK YOU FOR JOINING US.
THIS THERAPY IS BUILDING OFF A
10 PATIENT STUDY IN CHINA.
THE RESULTS OF THAT STUDY ARE
LIMITED.
WHAT INFORMATION GIVE YOU HOPE
THAT THIS WOULD WORK ON A BROAD
SCALE?
THE INFORMATION FROM THIS
INITIAL STUDY HAS BEEN
INCREDIBLY ENCOURAGING. THE
CHIEF OF THE JOURNAL THAT DID
THE TUTORIAL ON THE PAPER
COMMENTED HIS EXTRAORDINARY
RESULTS, BUT THEY NEED TO BE
VALIDATED BY LABS AND CLINICAL
TRIALS.
WE ARE HAPPY THAT THE FDA
APPROVED US TO DO SUCH CLINICAL
TRIALS OF THE UNIVERSITY OF
MIAMI.
THE NICE THING IS THAT WE WILL
HAVE THE RESULTS IN A VERY
SHORT TIME BECAUSE THESE CELLS
ARE LIKE INJECTING AN ARMY OF
CELLS, 200 MILLION OF CELLS
THAT WILL BE FIGHTING THE
COMPLICATIONS OF THE INFECTION
AND WE WILL KNOW WITHIN WEEKS
IF THERE IS A POSITIVE EFFECT.
THAT IS GREAT TO HEAR.
HOW MANY PATIENTS ARE IN THE
TRIAL?
WHEN DID YOU START? HAVE YOU
SEEN ANY RESULTS SO FAR?
WE HAVE A 24 PATIENTS IN
THIS INITIAL TRIAL.
WE DID NOT START THE FIRST
PATIENT. THE INITIAL RESULTS
ARE COMING FROM ISRAEL.
BUT WE ARE READY TO GO.
WE HAVE THE FIRST SIX DOSES
READY TO BE DELIVERED, AND
ANOTHER 25 DOSES READY TO
FOLLOW.
SO AS FAR AS CELLS APPLY IN THE
CLINICAL TRIAL WE ARE FINE AND
WE HOPE TO HAVE THE RESULTS
VERY SOON.
FOR THE LAYMAN LIKE US, CAN
YOU EXPLAIN WHY THE STEM CELLS
AND UP IN THE LONG?
THIS IS A NICE OFFICIAL, SO
TRADITIONALLY DID THIS TRIAL
FOR KIDNEY DISEASE.
IN THIS CASE, WHEN YOU INJECT
THE CELLS INTRAVENOUSLY, THE
FIRST FILTER IS THE LUNGS.
SO NATURALLY THE CELLS ARE
TRAPPED BY THE LONG BY AS MUCH
AS 95%.
SO IN THE CASE OF TARGETING THE
PANCREAS OR THE KIDNEY, YOU
HAVE TO DO AN INTERVENTION TO
PUT THE CATHETER IN THE ARTERY
THAT GOES TO THESE ORGANS.
BUT WHEN YOU TARGET THE LONG,
THIS IS A NATURAL WAY OF
DELIVERY AND THE CELLS GO
NATURALLY TO THE LUNG.
IN ADDITION, THE CELLS SENSE
INFLAMMATION AND THEY GO TARGET
THE SITE OF THE INFLAMMATION.
SO IN THIS CASE, A SIMPLE
INTRAVENOUS OR BLOOD PARENTS
USING WILL EXACTLY TARGET THE
LUNG THAT IS THE ORGAN THAT WE
WANT TO TREAT.
YES, BECAUSE THAT IS WHAT IS
ATTACKED BY DISTRESSFUL VIRUS.
BASED ON THE EXPERIENCE FROM
YOUR INTERNATIONAL CORROBORATE
HER'S AND ONGOING STEM CELL
TRIALS, HOW LONG DO YOU EXPECT
TO HAVE TO WAIT BEFORE YOU KNOW
IF THIS IS WORKING?
WE KNOW FROM THE RADIOLOGIC
EXAMINATION OF THE LUNGS FROM
THE STUDIES IN CHINA, FOR
EXAMPLE, THAT WITHIN DAYS, WE
SEE, LIKE IN THIS IMAGE, YOU
SEE FROM FEBRUARY 2nd TO
FEBRUARY 9, YOU HAVE THE
SOLUTION.
IT'S EASY THE GRAY AREAS OF THE
INFLAMMATION AND THE DEPOSITS
OF FLUID AND INFLAMMATORY
REACTION. AND WITHIN DAYS, YOU
JUST COMPLETELY RESOLVED THIS
KIND OF INFLAMMATION.
DR., WHAT IS THE TYPICAL
RECOVERY RATE FOR COVID
PATIENTS WHO HAVE BEEN PUT ON A
VENTILATOR?
IS THAT MEANT TREAT PATIENTS
BEFORE THEY GET TO THAT
CRITICAL STAGE?
THE TYPICAL RECOVERY RATE
THAT WE EXPECT WITH THIS
TREATMENT IS WITHIN ONE WEEK,
WE SHOULD KNOW.
THIS IS NOT A TRIAL THAT WILL
REQUIRE MONTHS OR YEARS OF
FALLOUT TO SEE IF THERE IS A
BENEFICIAL EFFECT OR NOT.
WE ARE CONFIDENT THAT WITHIN
DAYS OR A WEEK, WE WILL KNOW IF
THIS IS WORKING OR NOT AS SOON
AS WE START.
THAT SOUNDS VERY HOPEFUL.
IS THIS THERAPY MEANT TO
COMPLEMENT OTHER FORMS OF
THERAPY?
I THINK IT WILL DEFINITELY
BE USED AS A COMBINATION THERAPY
. WE WILL NOT EXCLUDE ANY OTHER
THERAPY AS PART OF THE
COMBINATION THERAPY.
WITH OTHER AGENTS IT MAY HELP
THIS AUTOIMMUNE REACTION, THIS
INFLAMMATORY REACTION, IT ALSO
THE PROBLEM THAT WE SEE IN
THESE PATIENTS.
I THINK IT IS IN A WAY A UNIQUE
THERAPY BECAUSE IT IS NOT JUST
FOR COVID-19, BUT IT IS FOR ANY
OF MY ROLES TARGETING THE LONG
WITH THESE MASSIVE REACTIONS.
IT WILL BE SOMETHING THAT WE
ARE PLANNING IN THE FUTURE TO
CREATE A REPOSITORY FOR RAPID
INTERVENTION IN RESPONSE TO ANY
PANDEMIC OR SITUATION IN WHICH
WE HAVE AN EMERGENCY THAT YOU
NEED TO TREAT AN INJURY TO THE
LONG OF SENSE DIMENSION.
IN THE MEANTIME, WHEN THERE IS
NOT A PANDEMIC SITUATION, YOU
CAN USE THESE CELLS, WE HAVE
TRIALS ONGOING THAT HAVE BEEN
AUTHORIZED BY THE FDA, FOR
ALZHEIMER'S, FOR KIDNEY
DISEASE, SO IT'S A CELL TYPE
THAT CAN BE USED IN MANY OTHER
SITUATIONS TO START NORMAL
ORGAN FUNCTIONS.
IT'S NOT JUST COVER 19.
QUICKLY, BEFORE WE WRAP UP,
PUT IT IN AS SIMPLE AS POSSIBLE
TERMS.
IF THIS SUCCEEDS, HOW BIG OF A
DEAL IS IT?
I THINK OF THIS SUCCEEDS IT
WILL BE A WAY TO TREAT THE
SEVERE CASES OF COVID-19 WHILE
WE WAIT FOR A VACCINE. ALSO TO
HAVE A REPOSITORY OF CELLS THAT
WOULD BE ABLE TO TREAT ANY
OTHER POSSIBLE PANDEMIC OR
EPIDEMIC OF THE LUNG. IT WILL BE
, IN THIS CASE, AN ARMY OF
CELLS READY TO BE USED FOR THIS
VIRAL INFECTION AND ALL THE
CONSEQUENCES IT CAN INDUCE IN
THE LUNG.
SO, HOPEFULLY WE WILL NOT SEE